Pediatric Drugs

, Volume 15, Issue 1, pp 1–8

Pharmacologic Intervention for Attention-Deficit Hyperactivity Disorder in Preschoolers

Is It Justified?
Current Opinion

Abstract

Pharmacologic intervention for attention-deficit hyperactivity disorder (ADHD) in preschool children is a controversial issue. Non-pharmacologic interventions (psychosocial and restricted dietary interventions) have been shown to benefit oppositional, non-compliant, aggressive and disruptive, as well as hyperactive and inattentive behaviors in preschoolers with ADHD and other disruptive behavior disorders. However, not all families have access to non-pharmacologic interventions or prefer them. The Preschool ADHD Treatment Study recently provided evidence of benefit with immediate-release methylphenidate; however, effect sizes were small to moderate and preschoolers had a high rate of adverse effects and a unique adverse effect profile. Furthermore, no information is available about long-term safety and effects of psychopharmacologic agents on the rapidly developing brains of preschoolers. Based on current evidence and guidelines, a careful trial with psychopharmacologic agents is indicated to treat ADHD in preschoolers if there is no improvement with behavior therapy and the preschoolers continue to exhibit significantly impaired hyperactive and inattentive symptoms. Preschoolers should be monitored closely for adverse effects and tried off medications after 6 months to assess the need for ongoing psychopharmacologic intervention. Further research is needed to identify predictors and moderators of response to guide individualized/optimal treatment options for ADHD in preschoolers.

References

  1. 1.
    Egger HL, Angold A. Common emotional and behavioral disorders in preschool children: presentation, nosology, and epidemiology. J Child Psychol Psychiatry. 2006;47(3–4):313–37.PubMedCrossRefGoogle Scholar
  2. 2.
    McDonnell M, Glod C. Prevalence of psychopathology in preschool-age children. J Child Adolesc Psychiatr Nursing. 2003;16(4):141–52.CrossRefGoogle Scholar
  3. 3.
    Campbell SB, Shaw DS, Gilliom M. Early externalizing behavior problems: toddlers and preschoolers at risk for later maladjustment. Dev Psychopathol. 2000;12(3):467–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Ghuman J, Arnold L, Anthony B. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol. 2008;18(5):413–47.PubMedCrossRefGoogle Scholar
  5. 5.
    Rappley MD, Mullan PB, Alvarez FJ, et al. Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children. Arch Pediatr Adolesc Med. 1999;153(10):1039–45.PubMedCrossRefGoogle Scholar
  6. 6.
    Baker B, Neece C, Fenning R, et al. Mental disorders in five-year-old children with or without developmental delay: focus on ADHD. J Clin Child Adolesc Psychol. 2010;39(4):492–505.PubMedCrossRefGoogle Scholar
  7. 7.
    Campbell SB, Ewing LJ. Follow-up of hard-to-manage preschoolers: adjustment at age 9 and predictors of continuing symptoms. J Child Psychol Psychiatry. 1990;31(6):871–89.PubMedCrossRefGoogle Scholar
  8. 8.
    Pliszka S, on behalf of the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.PubMedCrossRefGoogle Scholar
  9. 9.
    Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283(8):1025–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Zito JM, Safer DJ, Valluri S. Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. J Child Adolesc Psychopharmacol. 2007;17(2):195–203.PubMedCrossRefGoogle Scholar
  11. 11.
    Evans W, Morrill M, Parente S. Measuring inappropriate medical diagnosis and treatment in survey data: the case of ADHD among school-age children. J Health Econ. 2010;29(5):657–73.PubMedCrossRefGoogle Scholar
  12. 12.
    Hood KK, Eyberg SM. Outcomes of parent-child interaction therapy: mothers’ reports of maintenance three to six years after treatment. J Clin Child Adolesc Psychol. 2003;32(3):419–29.PubMedCrossRefGoogle Scholar
  13. 13.
    Jones K, Daley D, Hutchings J, et al. Efficacy of the incredible years basic parent training programme as an early intervention for children with conduct problems and ADHD. Child Care Health Dev. 2007;33(6):749–56.PubMedCrossRefGoogle Scholar
  14. 14.
    Kern L, DuPaul G, Volpe R, et al. Multisetting assessment-based intervention for young children at risk for attention deficit hyperactivity disorder: initial effects on academic and behavioral functioning. School Psychol Rev. 2007;36(2):237–55.Google Scholar
  15. 15.
    Sonuga-Barke EJ, Daley D, Thompson M, et al. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry. 2001;40(4):402–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Webster-Stratton C, Reid M, Beauchaine T. Combining parent and child training for young children with ADHD. J Clin Child Adolesc Psychol. 2011;40(2):191–203.PubMedCrossRefGoogle Scholar
  17. 17.
    Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1284–93.PubMedCrossRefGoogle Scholar
  18. 18.
    Dulcan MK, Benson RS. AACAP Official Action. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. J Am Acad Child Adolesc Psychiatry. 1997;36(9):1311–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1532–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Barkley RA, Shelton TL, Crosswait C, et al. Multi-method psycho-educational intervention for preschool children with disruptive behavior: preliminary results at post-treatment. J Child Psychol Psychiatry. 2000;41(3):319–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Shelton TL, Barkley RA, Crosswait C, et al. Multimethod psychoeducational intervention for preschool children with disruptive behavior: two-year post-treatment follow-up. J Abnorm Child Psychol. 2000;28(3):253–66.PubMedCrossRefGoogle Scholar
  22. 22.
    Dreyer A, O’Laughlin L, Moore J, et al. Parental adherence to clinical recommendations in an ADHD evaluation clinic. J Clin Psychol. 2010;66(10):1101–20.PubMedCrossRefGoogle Scholar
  23. 23.
    MacNaughton KL, Rodrigue JR. Predicting adherence to recommendations by parents of clinic-referred children. J Consult Clin Psychol. 2001;69(2):262–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Pelsser L, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377(9764):494–503.PubMedCrossRefGoogle Scholar
  25. 25.
    Ghuman J. Restricted elimination diet for ADHD: the INCA study. Lancet. 2011;377(9764):446–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Van Brunt DL, Johnston JA, Ye WY, et al. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2005;25(11):1541–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16(5):575–87.PubMedCrossRefGoogle Scholar
  28. 28.
    Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13–23.PubMedGoogle Scholar
  29. 29.
    Ghuman JK, Ginsburg GS, Subramaniam G, et al. Psychostimulants in preschool children with attention-deficit/hyperactivity disorder: clinical evidence from a developmental disorders institution. J Am Acad Child Adolesc Psychiatry. 2001;40(5):516–24.PubMedCrossRefGoogle Scholar
  30. 30.
    Ghuman J, Aman M, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol. 2009;19(4):329–39.PubMedCrossRefGoogle Scholar
  31. 31.
    Greenhill L, Swanson J, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40(2):180–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Ghuman JK, Riddle MA, Vitiello B, et al. Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007;17(5):563–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Vitiello B, Abikoff H, Chuang S, et al. Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007;17(5):593–604.PubMedCrossRefGoogle Scholar
  34. 34.
    Wigal S, Gupta S, Greenhill L, et al. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17(2):153–64.PubMedCrossRefGoogle Scholar
  35. 35.
    Wigal T, Greenhill L, Chuang S, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1294–303.PubMedCrossRefGoogle Scholar
  36. 36.
    Kratochvil C, Vaughan B, Stoner J, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics. 2011;127(4):862–8.CrossRefGoogle Scholar
  37. 37.
    Ghuman J, Aman M, Ghuman H, et al. Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(2):155–66.PubMedCrossRefGoogle Scholar
  38. 38.
    Ghuman J, Cataldo M, Beck M, et al. Behavioral training for pill-swallowing difficulties in young children with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14(4):601–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Ghuman J, Byreddy S, Ghuman H. Methylphenidate transdermal system in preschool children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(5):495–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Glantz L, Gilmore J, Hamer R, et al. Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood. Neuroscience. 2007;149(3):582–91.PubMedCrossRefGoogle Scholar
  41. 41.
    Huttenlocher PR. Morphometric study of human cerebral cortex development. Neuropsychologia. 1990;28(6):517–27.PubMedCrossRefGoogle Scholar
  42. 42.
    Chugani HT. Positron emission tomography: principles and applications in pediatrics. Mead Johnson Symp Perinat Dev Med. 1987;25:15–8.PubMedGoogle Scholar
  43. 43.
    Chugani H. A critical period of brain development: studies of cerebral glucose utilization with PET. Prev Med. 1998;27(2):184–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Crandall J, McCarthy D, Araki K, et al. Dopamine receptor activation modulates GABA neuron migration from the basal forebrain to the cerebral cortex. J Neurosci. 2007;27(14):3813–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Nasrallah H, Loney J, Olson S, et al. Cortical atrophy in young adults with a history of hyperactivity in childhood. Psychiatry Res. 1986;17(3):241–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Lou H, Hendricksen L, Bruhn P. Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder. Arch Neurol. 1984;41:825–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Shaw P, Sharp W, Morrison M, et al. Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder. Am J Psychiatry. 2009;166(1):58–63.PubMedCrossRefGoogle Scholar
  48. 48.
    Swanson J, Greenhill L, Wigal T, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304–13.PubMedCrossRefGoogle Scholar
  49. 49.
    Food and Drug Administration. Drug Safety and Risk Management Advisory Committee meeting, February 9, 2006: briefing January 12, 2006 [online]. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202B1_05_FDA-Tab05.pdf [Accessed 2012 Jan 27].
  50. 50.
    Nissen S. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Schelleman H, Bilker W, Strom B, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127(6):1102–10.PubMedCrossRefGoogle Scholar
  52. 52.
    Gould M, Walsh B, Munfakh J, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009;166(9):992–1001.PubMedCrossRefGoogle Scholar
  53. 53.
    El-Zein RA, Abdel-Rahman SZ, Hay MJ, et al. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 2005;230(2):284–91.PubMedCrossRefGoogle Scholar
  54. 54.
    Tucker J, Suter W, Petibone D, et al. Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. Mutat Res. 2009;677(1–2):53–8.PubMedGoogle Scholar
  55. 55.
    Walitza S, Kampf K, Artamonov N, et al. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. Toxicol Lett. 2009;184(1):38–43.PubMedCrossRefGoogle Scholar
  56. 56.
    Walitza S, Kampf K, Oli R, et al. Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children. Toxicol Lett. 2010;193(1):4–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Zamora-Perez A, Lazalde-Ramos B, Sosa-Maclas M, et al. Methylphenidate lacks genotoxic effects in mouse peripheral blood erythrocytes. Drug Chem Toxicol. 2011;34(3):294–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Perrin J, Friedman R, Knilans T et al. on behalf of the Black Box Working Group and the Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008; 122(2):451–3.Google Scholar
  59. 59.
    Vetter V, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(8):2407–23.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  1. 1.Child and Adolescent Psychiatry, University of ArizonaTucsonUSA

Personalised recommendations